靶点- |
作用机制- |
|
|
|
|
最高研发阶段临床2期 |
首次获批国家/地区- |
首次获批日期- |
A randomized double blind placebo controlled multicenter phase III study to evaluate the efficacy and safety of Nuvastatic® 300 mg in reducing chemotherapy induced fatigue in patients with metastatic triple negative breast cancer receiving standard chemotherapy - NIL
A randomized double blind placebo controlled parallel group comparative phase III study to evaluate the efficacy and safety of Nuvastatic® 300mg in reducing cancerinduced fatigue in patients with newly diagnosed chemotherapy naïve nonresectable metastatic colorectal cancer receiving standard chemotherapy - NIL
/ Not yet recruiting临床2/3期 A randomized, double-blind, placebo-controlled, multicenter, phase II/III study to evaluate the efficacy and safety of Nuvastatic® in reducing chemotherapy-induced fatigue in patients with metastatic colorectal cancer receiving 5-fluorouracil.
100 项与 Natureceuticals Sdn. Bhd. 相关的临床结果
0 项与 Natureceuticals Sdn. Bhd. 相关的专利(医药)
100 项与 Natureceuticals Sdn. Bhd. 相关的药物交易
100 项与 Natureceuticals Sdn. Bhd. 相关的转化医学